1. Home
  2. VTYX vs CEP Comparison

VTYX vs CEP Comparison

Compare VTYX & CEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VTYX
  • CEP
  • Stock Information
  • Founded
  • VTYX 2018
  • CEP 2020
  • Country
  • VTYX United States
  • CEP United States
  • Employees
  • VTYX N/A
  • CEP N/A
  • Industry
  • VTYX Medicinal Chemicals and Botanical Products
  • CEP
  • Sector
  • VTYX Health Care
  • CEP
  • Exchange
  • VTYX Nasdaq
  • CEP NYSE
  • Market Cap
  • VTYX 154.9M
  • CEP 133.8M
  • IPO Year
  • VTYX 2021
  • CEP 2024
  • Fundamental
  • Price
  • VTYX $1.61
  • CEP $10.38
  • Analyst Decision
  • VTYX Buy
  • CEP
  • Analyst Count
  • VTYX 4
  • CEP 0
  • Target Price
  • VTYX $11.33
  • CEP N/A
  • AVG Volume (30 Days)
  • VTYX 1.3M
  • CEP 3.2K
  • Earning Date
  • VTYX 03-04-2025
  • CEP 01-01-0001
  • Dividend Yield
  • VTYX N/A
  • CEP N/A
  • EPS Growth
  • VTYX N/A
  • CEP N/A
  • EPS
  • VTYX N/A
  • CEP 0.06
  • Revenue
  • VTYX N/A
  • CEP N/A
  • Revenue This Year
  • VTYX N/A
  • CEP N/A
  • Revenue Next Year
  • VTYX N/A
  • CEP N/A
  • P/E Ratio
  • VTYX N/A
  • CEP $187.78
  • Revenue Growth
  • VTYX N/A
  • CEP N/A
  • 52 Week Low
  • VTYX $1.57
  • CEP $9.99
  • 52 Week High
  • VTYX $11.48
  • CEP $10.95
  • Technical
  • Relative Strength Index (RSI)
  • VTYX 34.49
  • CEP N/A
  • Support Level
  • VTYX $1.57
  • CEP N/A
  • Resistance Level
  • VTYX $1.78
  • CEP N/A
  • Average True Range (ATR)
  • VTYX 0.10
  • CEP 0.00
  • MACD
  • VTYX -0.00
  • CEP 0.00
  • Stochastic Oscillator
  • VTYX 10.26
  • CEP 0.00

About VTYX Ventyx Biosciences Inc.

Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.

About CEP CANTOR EQUITY PARTNERS INC

Cantor Equity Partners Inc is a blank check company.

Share on Social Networks: